Key result
Dual-release olmesartan and metoprolol capsules achieve ~96% olmesartan entrapment efficiency in optimized formulation.
Why the study?
Morning blood pressure surge increases cardiovascular risk due to circadian activation of the renin-angiotensin-aldosterone and sympathetic nervous systems, motivating the development of a dual-release multiparticulate capsule for chronotherapeutic management of circadian hypertension.
This pharmaceutical formulation study demonstrates that a Quality by Design-optimized multiparticulate capsule can successfully achieve immediate release of olmesartan and pH-dependent delayed release of metoprolol in vitro, offering a potential chronotherapeutic dosage form for targeting the morning blood pressure surge.
Answers are grounded in this paper and cite their sources.
May support chronotherapeutic formulation development for morning BP surge; leaves open clinical efficacy and safety in humans.
Purpose: Morning blood pressure surge increases cardiovascular risk due to circadian activation of the renin–angiotensin–aldosterone and sympathetic nervous systems. This study developed a Quality by Design (QbD)-based dual-release multiparticulate capsule providing immediate release of olmesartan medoxomil followed by pH-responsive delayed release of metoprolol succinate for chronotherapeutic management of circadian hypertension. Methods: Immediate and delayed-release pellets were prepared by extrusion-spheronization and optimized using Response Surface Methodology with a Box-Behnken Design. Critical formulation variables were optimized to maximize entrapment efficiency, production yield, and drug release. Optimized formulations were evaluated by FTIR, SEM, dissolution studies, release kinetics, and accelerated stability testing. Results: Optimized formulations showed excellent agreement with the quadratic models (R² = 0.9915–0.9988; p < 0.0001). Immediate-release olmesartan pellets provided rapid drug release, while Eudragit-coated metoprolol pellets minimized gastric release and achieved controlled intestinal release. The optimized capsule exhibited satisfactory physicochemical properties, high content uniformity, low friability, reproducible sequential drug release, and acceptable accelerated stability. Conclusion: The QbD-based multiparticulate system successfully combined immediate and delayed drug release in a single chronotherapeutic dosage form. The optimized formulation established a robust design space and demonstrated the potential of sequential multiparticulate delivery for improving management of the early morning hypertension surge.
No takes yet. Share an insight, caveat, or question.
Haribut et al. (2026) studied Circadian hypertension (morning blood pressure surge). QbD-engineered dual-release multiparticulate capsule (immediate-release olmesartan medoxomil and pH-responsive delayed-release metoprolol succinate) was evaluated on Entrapment efficiency, production yield, and in vitro drug release via Box-Behnken Design quadratic modeling (R² 0.9915-0.9988, p=<0.0001). Optimized dual-release multiparticulate capsules of olmesartan and metoprolol showed strong quadratic model fit and 96.18% olmesartan entrapment efficiency.
Synapse has enriched 10 related papers. Consider them for comparative context: